US Health Authorities have given the green light to two companies to start clinical trials for kidney transplantation from pigs to humans, a practice that gives rise to hopes to help cover chronic lack of organs.

Xenomotia, as it is called the transplantation of tissues or organs from animals to humans, is still in the experimental stage. The goal is to tackle the lack of organs, especially in the US, where more than 100,000 patients are on the list and are waiting for a graft – more than 90,000 are expecting a compatible kidney.

OR United Therapeutics and Egenesistwo US companies are trying to develop genetically modified pig organs that can be transplanted to humans and say they have received permission to start clinical trials. This “represents an important step in our mission, the aim of which is to increase the availability of instruments,” said Lee Peterson, a senior United Cemetery official.

By 2021, the two companies have made many experimental strain sections in patients who were clinically dead or in a very severe condition.

In November, Theuana Luney, a patient from Alabama for which she could not find a compatible donor while her health deteriorated, received a kidney kid from United Therapeutics. At the end of January, the 50 -year -old woman became the first man in the world to survive for two months after strangulation. Her condition is good, a hospital spokesman assured today.

OR United Therapeutics He announced that it would take a clinical trial, initially with six patients suffering from end -stage renal failure and may extend it to 50 people. The first strangulation will take place in the middle of the year, he said.

The competing company Egenesis will start the test with three patients who are little chance of finding a compatible donor.